CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade OPKO Health, Inc. - OPK CFD

1.4621
1.39%
0.0258
Low: 1.3822
High: 1.4621
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0258
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.4421
Open* 1.4321
1-Year Change* -62.8%
Day's Range* 1.3822 - 1.3822
52 wk Range 1.43-5.25
Average Volume (10 days) 2.75899
Average Volume (3 months) 48.7348
Market Cap 1135.85
P/E Ratio N/A
Shares Outstanding 772686000
Revenue 1220.19
EPS -0.45446
Dividend (Yield %) N/A
Beta 1.66118
Next Earnings Date Feb 22, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 2, 2022 1.4621 0.0450 3.18% 1.4171 1.4621 1.3822
Dec 1, 2022 1.4421 -0.0449 -3.02% 1.4870 1.5319 1.4122
Nov 30, 2022 1.4820 0.0649 4.58% 1.4171 1.4870 1.3673
Nov 29, 2022 1.4022 0.0050 0.36% 1.3972 1.4371 1.3722
Nov 28, 2022 1.3822 -0.0400 -2.81% 1.4222 1.4271 1.3523
Nov 25, 2022 1.4571 -0.0099 -0.67% 1.4670 1.4970 1.4321
Nov 23, 2022 1.4820 0.0199 1.36% 1.4621 1.4920 1.4521
Nov 22, 2022 1.4521 -0.1048 -6.73% 1.5569 1.5569 1.4222
Nov 21, 2022 1.5719 0.0150 0.96% 1.5569 1.5968 1.5519
Nov 18, 2022 1.6068 0.0000 0.00% 1.6068 1.6517 1.5569
Nov 17, 2022 1.6118 -0.0499 -3.00% 1.6617 1.6617 1.5719
Nov 16, 2022 1.6817 -0.0299 -1.75% 1.7116 1.7316 1.6717
Nov 15, 2022 1.7416 0.0150 0.87% 1.7266 1.7615 1.7116
Nov 14, 2022 1.6916 0.0249 1.49% 1.6667 1.7016 1.6318
Nov 11, 2022 1.6467 0.0798 5.09% 1.5669 1.6567 1.5519
Nov 10, 2022 1.5669 -0.0299 -1.87% 1.5968 1.6218 1.5020
Nov 9, 2022 1.5220 -0.2395 -13.60% 1.7615 1.7765 1.5170
Nov 8, 2022 1.8314 0.0250 1.38% 1.8064 1.8913 1.7565
Nov 7, 2022 1.8014 0.0249 1.40% 1.7765 1.8114 1.7565
Nov 4, 2022 1.7500 -0.0100 -0.57% 1.7600 1.8000 1.6900

OPKO Health, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 1117.49 966.006 990.266 901.935 1435.41 1774.72
Revenue 1117.49 966.006 990.266 901.935 1435.41 1774.72
Cost of Revenue, Total 611.482 620.13 604.636 572.484 894.408 1193.19
Gross Profit 506.012 345.876 385.63 329.451 541.005 581.524
Total Operating Expense 1214.05 1242.45 1161.46 1175.99 1377.7 1755.97
Selling/General/Admin. Expenses, Total 398.431 408.828 353.446 340.305 354.573 468.857
Research & Development 113.871 126.435 125.586 117.87 75.316 76.85
Depreciation / Amortization 64.407 71.484 67.933 64.783 56.391 50.278
Unusual Expense (Income) 8.9 18.994 26.678 95.399 1 -31.508
Other Operating Expenses, Total 16.954 -3.423 -16.816 -14.854 -3.989 -1.703
Operating Income -96.551 -276.442 -171.197 -274.052 57.714 18.75
Interest Income (Expense), Net Non-Operating -4.174 -5.939 -7.607 -19.632 -21.732 -18.006
Other, Net 3.903 10.457 1.535 -11.281 12.701 -14.77
Net Income Before Taxes -96.822 -271.924 -177.269 -304.965 48.683 -14.026
Net Income After Taxes -40.707 -290.779 -138.543 -312.025 31.066 -29.515
Equity In Affiliates -7.652 -14.471 -14.497 -2.9 -0.48 -0.629
Net Income Before Extra. Items -48.359 -305.25 -153.04 -314.925 30.586 -30.144
Net Income -48.359 -305.25 -153.04 -314.925 30.586 -30.144
Income Available to Common Excl. Extra. Items -48.359 -305.25 -153.04 -314.925 30.586 -30.143
Income Available to Common Incl. Extra. Items -48.359 -305.25 -153.04 -314.925 30.586 -30.143
Diluted Net Income -48.359 -305.25 -153.04 -314.925 30.586 -30.143
Diluted Weighted Average Shares 550.847 559.161 563.144 595.454 640.655 648.078
Diluted EPS Excluding Extraordinary Items -0.08779 -0.54591 -0.27176 -0.52888 0.04774 -0.04651
Diluted Normalized EPS -0.07729 -0.52383 -0.24097 -0.42474 0.04874 -0.07811
Total Extraordinary Items 0
Total Adjustments to Net Income 0.001
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 545.165 442.408 385.813 401.331 329.219
Revenue 545.165 442.408 385.813 401.331 329.219
Cost of Revenue, Total 363.507 292.908 243.957 292.823 243.875
Gross Profit 181.658 149.5 141.856 108.508 85.344
Total Operating Expense 506.728 436.837 347.987 464.415 401.643
Selling/General/Admin. Expenses, Total 112.286 113.236 105.12 138.214 117.537
Research & Development 19.315 18.222 18.306 21.007 18.312
Depreciation / Amortization 12.577 12.574 12.609 12.518 22.025
Other Operating Expenses, Total -0.957 -0.103 -0.497 -0.147 -0.106
Operating Income 38.437 5.571 37.826 -63.084 -72.424
Interest Income (Expense), Net Non-Operating -5.829 -5.153 -2.998 -4.026 -2.784
Other, Net -0.927 -11.783 -3.356 1.297 -1.442
Net Income Before Taxes 31.681 -11.365 31.472 -65.813 -76.65
Net Income After Taxes 31.121 -16.119 28.792 -73.309 -55.384
Equity In Affiliates -0.043 -0.067 -0.053 -0.466 -0.049
Net Income Before Extra. Items 31.078 -16.186 28.739 -73.775 -55.433
Net Income 31.078 -16.186 28.739 -73.775 -55.433
Income Available to Common Excl. Extra. Items 31.078 -16.186 28.739 -73.774 -55.433
Income Available to Common Incl. Extra. Items 31.078 -16.186 28.739 -73.774 -55.433
Diluted Net Income 31.078 -16.186 28.739 -73.774 -55.433
Diluted Weighted Average Shares 640.853 646.997 651.843 652.18 660.302
Diluted EPS Excluding Extraordinary Items 0.04849 -0.02502 0.04409 -0.11312 -0.08395
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.04849 -0.02502 0.01267 -0.11312 -0.08395
Unusual Expense (Income) -31.508 0
Total Adjustments to Net Income 0.001
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 483.601 348.861 317.731 324.045 523.179 823.013
Cash and Short Term Investments 168.733 91.499 96.473 85.452 72.211 134.71
Cash & Equivalents 168.733 91.499 96.473 85.452 72.211 134.71
Total Receivables, Net 249.492 192.892 161.983 157.687 302.256 265.588
Accounts Receivable - Trade, Net 220.284 165.516 143.907 134.617 286.314 259.637
Total Inventory 47.228 49.333 42.299 53.434 132.341 86.502
Prepaid Expenses 10.64 11.739 13.129 11.633 11.062 15.024
Other Current Assets, Total 7.508 3.398 3.847 15.839 5.309 321.189
Total Assets 2766.62 2589.96 2451.07 2309.27 2473.06 2399.72
Property/Plant/Equipment, Total - Net 122.831 146.557 144.674 166.491 178.289 123.955
Property/Plant/Equipment, Total - Gross 79.509 232.404 256.336 302.936 343.058 257.281
Accumulated Depreciation, Total -56.778 -85.847 -111.662 -136.445 -164.769 -133.326
Goodwill, Net 704.603 717.099 700.193 671.94 680.602 520.601
Intangibles, Net 1408.69 1331.18 1250.02 1119.16 1065.2 911.883
Long Term Investments 37.122 37.309 30.373 20.626 15.731 10.729
Other Long Term Assets, Total 9.773 8.948 8.077 7.008 10.06 9.534
Total Current Liabilities 263.296 312.029 288.321 249.119 375.483 330.008
Accounts Payable 53.36 74.307 47.395 62.537 100.883 82.04
Accrued Expenses 117.066 160.588 133.476 154.891 231.661 202.602
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 15.006 15.325 40.693 12.362 27.156 16.952
Other Current Liabilities, Total 77.864 61.809 66.757 19.329 15.783 28.414
Total Liabilities 674.811 746.333 659.781 694.513 801.512 714.589
Total Long Term Debt 73.707 142.665 172.771 263.909 228.631 193.083
Long Term Debt 66.491 134.879 167.151 259.863 225.826 190.159
Capital Lease Obligations 7.216 7.786 5.62 4.046 2.805 2.924
Deferred Income Tax 165.331 148.729 115.193 118.717 137.208 148.487
Other Liabilities, Total 172.477 142.91 83.496 62.768 60.19 43.011
Total Equity 2091.81 1843.62 1791.29 1614.76 1671.55 1685.13
Common Stock 5.586 5.6 5.869 6.704 6.706 6.901
Additional Paid-In Capital 2845.1 2889.26 3004.42 3142.99 3152.69 3222.49
Retained Earnings (Accumulated Deficit) -729.954 -1048.91 -1197.08 -1511.08 -1481.83 -1511.98
Treasury Stock - Common -1.911 -1.791 -1.791 -1.791 -1.791 -1.791
Unrealized Gain (Loss) -0.263 4.876 0
Other Equity, Total -26.746 -5.404 -20.131 -22.07 -4.225 -30.495
Total Liabilities & Shareholders’ Equity 2766.62 2589.96 2451.07 2309.27 2473.06 2399.72
Total Common Shares Outstanding 557.989 559.474 586.332 669.829 670.036 681.427
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 599.049 547.029 557.51 823.013 754.069
Cash and Short Term Investments 89.503 65.757 148.599 134.71 102.281
Cash & Equivalents 89.503 65.757 148.599 134.71 102.281
Total Receivables, Net 330.293 275.639 265.527 265.588 221.295
Accounts Receivable - Trade, Net 320.462 265.856 255.192 259.637 212.755
Total Inventory 159.104 134.722 112.861 86.502 99.406
Prepaid Expenses 15.086 21.967 19.52 15.024 9.902
Other Current Assets, Total 5.063 48.944 11.003 321.189 321.185
Total Assets 2519.57 2421.65 2417.64 2399.72 2306.86
Property/Plant/Equipment, Total - Net 177.7 143.001 141.002 123.955 124.667
Goodwill, Net 676.162 677.36 674.574 520.601 519.052
Intangibles, Net 1046.51 1035.71 1024.06 911.883 890.498
Long Term Investments 10.41 8.945 11.753 10.729 9.472
Other Long Term Assets, Total 9.745 9.6 8.744 9.534 9.1
Total Current Liabilities 403.93 303.98 283.035 330.008 309.17
Accounts Payable 162.69 88.512 94.393 82.04 94.24
Accrued Expenses 206.106 186.79 168.936 202.602 166.297
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 20.103 20.045 16.702 16.952 19.863
Other Current Liabilities, Total 15.031 8.633 3.004 28.414 28.77
Total Liabilities 823.061 679.065 652.071 714.589 691.974
Total Long Term Debt 230.613 189.727 189.516 193.083 216.358
Long Term Debt 228.107 187.168 187.214 190.159 212.493
Capital Lease Obligations 2.506 2.559 2.302 2.924 3.865
Deferred Income Tax 135.244 136.416 134.247 148.487 125.03
Other Liabilities, Total 53.274 48.942 45.273 43.011 41.416
Total Equity 1696.51 1742.58 1765.57 1685.13 1614.88
Common Stock 6.707 6.898 6.9 6.901 6.902
Additional Paid-In Capital 3155.65 3214.35 3218.58 3222.49 3191.14
Retained Earnings (Accumulated Deficit) -1450.76 -1466.94 -1438.2 -1511.98 -1549.95
Treasury Stock - Common -1.791 -1.791 -1.791 -1.791 -1.791
Other Equity, Total -13.295 -9.932 -19.923 -30.495 -31.415
Total Liabilities & Shareholders’ Equity 2519.57 2421.65 2417.64 2399.72 2306.86
Total Common Shares Outstanding 670.153 681.163 681.342 681.427 681.483
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -48.359 -305.25 -153.04 -314.925 30.586 -30.143
Cash From Operating Activities 32.046 -92.08 -109.141 -172.522 39.476 38.337
Cash From Operating Activities 96.576 102.093 97.344 93.807 85.362 78.716
Deferred Taxes -66.3 16.092 -35.133 4.324 15.64 10.159
Non-Cash Items 70.062 46.633 39.832 113.079 5.497 0.087
Cash Taxes Paid -27.122 5.416 1.41 -2.667 0.903 5.969
Cash Interest Paid 2.89 1.313 2.076 11.873 10.908 8.515
Changes in Working Capital -19.933 48.352 -58.144 -68.807 -97.609 -20.482
Cash From Investing Activities -20.702 -46.667 -26.119 -13.27 -18.327 35.949
Capital Expenditures -23.547 -46.524 -27.858 -12.741 -33.682 -32.156
Other Investing Cash Flow Items, Total 2.845 -0.143 1.739 -0.529 15.355 68.105
Cash From Financing Activities -35.195 61.043 140.909 175.248 -35.076 -10.351
Issuance (Retirement) of Stock, Net 8.576 2.132 148.673 276.352 0.756 1.08
Issuance (Retirement) of Debt, Net -43.771 58.911 -7.764 -93.342 -35.832 -11.243
Foreign Exchange Effects -1.014 0.47 -0.675 -0.477 0.686 -1.436
Net Change in Cash -24.865 -77.234 4.974 -11.021 -13.241 62.499
Financing Cash Flow Items -7.762 0 -0.188
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 31.078 14.892 43.631 -30.143 -55.433
Cash From Operating Activities 26.037 10.584 43.98 38.337 -19.856
Cash From Operating Activities 19.989 40.561 59.525 78.716 27.814
Deferred Taxes -1.033 2.479 2.378 10.159 -22.356
Non-Cash Items 1.222 19.401 -9.952 0.087 9.879
Cash Taxes Paid 1.47 3.69 5.509 5.969 1.063
Cash Interest Paid 4.689 4.883 8.386 8.515 3.42
Changes in Working Capital -25.219 -66.749 -51.602 -20.482 20.24
Cash From Investing Activities -1.106 -9.948 44.628 35.949 -4.903
Capital Expenditures -9.245 -18.192 -25.426 -32.156 -5.251
Other Investing Cash Flow Items, Total 8.139 8.244 70.054 68.105 0.348
Cash From Financing Activities -7.192 -6.927 -11.183 -10.351 -7.891
Issuance (Retirement) of Stock, Net 0.308 0.466 0.879 1.08 0.136
Issuance (Retirement) of Debt, Net -7.5 -7.393 -11.874 -11.243 -8.027
Foreign Exchange Effects -0.447 -0.163 -1.037 -1.436 0.221
Net Change in Cash 17.292 -6.454 76.388 62.499 -32.429
Financing Cash Flow Items -0.188 -0.188

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

OPKO Health, Inc. Company profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company''s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Industry: Pharmaceuticals (NEC)

4400 Biscayne Blvd.
MIAMI
FLORIDA 33137
US

Income Statement

People also watch

Oil - Crude

80.34 Price
-1.310% 1D Chg, %
Long position overnight fee -0.0024%
Short position overnight fee -0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

11,963.60 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0166%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 3.3

Natural Gas

6.21 Price
-8.960% 1D Chg, %
Long position overnight fee 0.0408%
Short position overnight fee -0.0658%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

17,061.95 Price
+0.440% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading